CN107050049A - 一种治疗深部真菌性皮肤病的外用杀菌剂 - Google Patents
一种治疗深部真菌性皮肤病的外用杀菌剂 Download PDFInfo
- Publication number
- CN107050049A CN107050049A CN201710327689.2A CN201710327689A CN107050049A CN 107050049 A CN107050049 A CN 107050049A CN 201710327689 A CN201710327689 A CN 201710327689A CN 107050049 A CN107050049 A CN 107050049A
- Authority
- CN
- China
- Prior art keywords
- parts
- external application
- deep fungal
- bactericide
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 63
- 230000002538 fungal effect Effects 0.000 title claims abstract description 61
- 239000003899 bactericide agent Substances 0.000 title claims abstract description 59
- 208000017520 skin disease Diseases 0.000 title claims abstract description 54
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 42
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 40
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 40
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 21
- 239000004471 Glycine Substances 0.000 claims abstract description 21
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 21
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000004327 boric acid Substances 0.000 claims abstract description 21
- 229940033123 tannic acid Drugs 0.000 claims abstract description 21
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 21
- 229920002258 tannic acid Polymers 0.000 claims abstract description 21
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 20
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 20
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 20
- 208000010195 Onychomycosis Diseases 0.000 claims abstract description 8
- 201000005882 tinea unguium Diseases 0.000 claims abstract description 8
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 6
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 6
- 208000024780 Urticaria Diseases 0.000 claims abstract description 5
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 34
- 235000011187 glycerol Nutrition 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000008213 purified water Substances 0.000 claims description 12
- 210000002683 foot Anatomy 0.000 claims description 8
- 201000004647 tinea pedis Diseases 0.000 claims description 8
- 230000004060 metabolic process Effects 0.000 claims description 5
- 241000272814 Anser sp. Species 0.000 claims description 4
- 206010043866 Tinea capitis Diseases 0.000 claims description 4
- 201000010618 Tinea cruris Diseases 0.000 claims description 3
- 206010067197 Tinea manuum Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 210000004761 scalp Anatomy 0.000 claims description 3
- 208000009189 tinea favosa Diseases 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 10
- 208000002474 Tinea Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 7
- 241000130764 Tinea Species 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 230000000638 stimulation Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 235000001916 dieting Nutrition 0.000 abstract description 2
- 230000037228 dieting effect Effects 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- 239000002994 raw material Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 241000893966 Trichophyton verrucosum Species 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 240000000203 Salix gracilistyla Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 206010052366 systemic mycosis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗深部真菌性皮肤病的外用杀菌剂,所述外用杀菌剂按照质量份数包括:甘氨酸3~12份、硼酸1~9份、单宁酸3~8份、水杨酸5~12份和苯甲酸6~12份。本发明的治疗深部真菌性皮肤病的外用杀菌剂,采用多种具有抗菌、消炎、收敛的化合物合理搭配,各成分以相应比例制备后,分为三种剂型,患者根据病症选取不同药物辅以靶向定位疗法,药力快速抵达患处,对深部真菌类手足癣、灰指甲、湿疹、寻麻疹及各种癣类皮肤病疗效显著,且对皮肤无任何刺激作用,用药期间无需忌口,适用于各类人群。
Description
技术领域
本发明涉及中药技术领域,具体涉及一种治疗深部真菌性皮肤病的外用杀菌剂。
背景技术
现在,随着生活压力的增大和人们饮食的不规律,外出交流活动的增多,越来越多的人换上皮肤疾病,如灰指甲、湿疹、脚气、脚癣、鹅掌风、皮癣等,大都是由病原真菌所引起的人类皮肤以及黏膜、毛发和甲等皮肤附属器的一大类感染性疾病,包括侵犯表皮及皮肤附属器的深部真菌性皮肤病、侵犯皮下组织的深部真菌性皮肤病及播散性真菌病。
现代医学认为,真菌性皮肤病指手,足,甲癣指(趾)间及掌、跖皮肤的深部真菌感染,称为手癣和足癣,侵犯指(趾)甲者称为甲癣。深部真菌病在皮肤科门诊中是常见病、多发病,发病率占门诊患者总数的第二或第三位,有的医院甚至居首位。致病菌皮肤癣菌主要分毛癣菌属、孢子菌属和表皮癣菌属三大类,感染人体皮肤后会发生红斑丘疹、水疱、鳞屑、断发、脱发和甲板改变等。按其侵犯部位差别,临床可分为头癣、体癣、股癣、手足癣和甲癣。
中医认为此类病症多为生活、起居不慎,外感湿、热、虫、毒,或相互接触传染,感染深部真菌,诸邪相合,郁于腠理,淫于皮肤所致。发于上部者,多兼风邪,而发为白秃疮、肥疮、鹅掌风等;发于下部者,多为湿盛,而发为脚湿气等。风热偏盛者,则多表现为发落起疹、瘙痒脱屑;湿热盛者,则多渗液流滋、瘙痒结痂;郁热化燥,气血失和,肌肤失养,则皮肤肥厚、燥裂、瘙痒。
目前采用西药治疗易产生毒副作用,疗效不明显或无疗效,且易复发,给患者的生活、工作及心理、社交带来极大的困扰。因此,本发明研制了一种能够快速治愈深部真菌引起的各种皮肤病,而且治愈率高、成本低、易代谢。
发明内容
本发明的目的在于提供一种治疗深部真菌性皮肤病的外用杀菌剂,用以解决现有技术中存在的问题。
为实现上述目的,本发明提供了一种治疗深部真菌性皮肤病的外用杀菌剂。具体地,所述外用杀菌剂按照质量份数包括:甘氨酸3~12份、硼酸1~9份、单宁酸3~8份、水杨酸5~12份和苯甲酸6~12份。
优选地,所述外用杀菌剂按照质量份数还包括丙三醇3~80份。
优选地,所述丙三醇的浓度为50%或100%的丙三醇溶液。
优选地,所述外用杀菌剂按照质量份数包括:甘氨酸3~8份、硼酸3~7份、单宁酸3~7份、水杨酸8~12份、苯甲酸6~12份、100%丙三醇溶液3~8份和纯化水18~35份。
优选地,所述外用杀菌剂按照质量份数包括:甘氨酸5~10份、硼酸1~5份、单宁酸3~8份、水杨酸6~10份、苯甲酸5~8份、50%丙三醇溶液60~80份和纯化水20~30份。
优选地,所述外用杀菌剂按照质量份数包括:甘氨酸8~12份,硼酸4~9份,单宁酸5~8份,水杨酸5~8份和苯甲酸6~10份。
优选地,用于杀菌、去腐生肌、促进新陈代谢及治疗灰指甲。
优选地,用于治疗深部真菌引起的头癣、手癣、足癣、股癣及湿疹、寻麻疹。
优选地,用于治疗深部真菌引起的脚气、脚臭、下肢慢性溃疡及鹅掌疯。
本发明具有如下优点:
1、本发明的治疗深部真菌性皮肤病的外用杀菌剂,采用多种具有抗菌、消炎、收敛的化合物合理搭配,且分为不同的三种剂型,患者根据病症选取不同药物辅以靶向定位疗法,药力快速抵达患处,具有强效杀菌、特异性强、药效持久的特点。其次,本发明的外用杀菌剂对皮肤无任何刺激作用,用药期间无需忌口,适用于各类人群。
2、本发明的治疗深部真菌性皮肤病的外用杀菌剂,原材料易于取得、制备方法简单,成本低,各成分以相应比例配伍制备后,其治疗作用显著增加,对深部真菌类手足癣、灰指甲、湿疹、寻麻疹及各种癣类皮肤病疗效显著。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸5份,硼酸4份,单宁酸4份,水杨酸10份,苯甲酸9份,浓度为100%丙三醇溶液5份,纯化水27份。
实施例2
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸3份,硼酸4份,单宁酸3份,水杨酸11份,苯甲酸12份,浓度为100%丙三醇溶液7份,纯化水20份。
实施例3
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸6份,硼酸7份,单宁酸6份,水杨酸9份,苯甲酸11份,浓度为100%丙三醇溶液8份,纯化水35份。
实施例4
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸8份,硼酸5份,单宁酸4份,水杨酸10份,苯甲酸6份,浓度为100%丙三醇溶液3份,纯化水18份。
本发明实施例1~4制备的治疗深部真菌性皮肤病的外用杀菌剂为Ⅰ型(膏状),治疗过程中利用靶向定位疗法,直接将Ⅰ型治疗深部真菌性皮肤病的外用杀菌剂敷在患处(例如灰指甲)包好,五至七天的时间。本实施例1~4制备的Ⅰ型治疗深部真菌性皮肤病的外用杀菌剂,能深入肌肤内深处杀死深部真菌,促进患处新陈代谢,修复患处,到期后将敷在患处的药包拆下即可,并清除患处和周边所有代谢产物,间隔2~3天后继续用药,直至指甲康复,愈后不复发。
另外,本发明实施例1~4制备的Ⅰ型治疗深部真菌性皮肤病的外用杀菌剂不同于其他药物在治疗过程中需要软化指甲(烂),甚至削、拔指甲等治疗方式,不损伤指甲及皮肤。
实施例5
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸8份、硼酸3份、单宁酸5份、水杨酸7份、苯甲酸6份、50%丙三醇溶液70份和纯化水25份。
实施例6
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸5份、硼酸1份、单宁酸3份、水杨酸9份、苯甲酸5份、50%丙三醇溶液65份和纯化水30份。
实施例7
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸7份、硼酸5份、单宁酸8份、水杨酸6份、苯甲酸8份、50%丙三醇溶液80份和纯化水22份。
实施例8
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸10份、硼酸2份、单宁酸6份、水杨酸10份、苯甲酸7份、50%丙三醇溶液60份和纯化水20份。
本发明实施例5~8制备的治疗深部真菌性皮肤病的外用杀菌剂为Ⅱ型(液体),治疗过程中利用靶向定位疗法,将Ⅱ型治疗深部真菌性皮肤病的外用杀菌剂涂抺于患处,早晚各一次。当遇到病情较严重的湿疹、寻麻疹及各种癣类皮肤病,需要与Ⅰ型治疗深部真菌性皮肤病的外用杀菌剂配合使用(先涂抹Ⅱ型治疗深部真菌性皮肤病的外用杀菌剂,再敷Ⅰ型治疗深部真菌性皮肤病的外用杀菌剂)。
另外,本发明实施例5~8制备的Ⅱ型治疗深部真菌性皮肤病的外用杀菌剂使用方便,渗透力强,杀菌效果好,无任何副作用。
实施例9
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸10份,硼酸6份,单宁酸7份,水杨酸6份和苯甲酸8份。
实施例10
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸9份,硼酸4份,单宁酸8份,水杨酸5份和苯甲酸6份。
实施例11
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸12份,硼酸5份,单宁酸5份,水杨酸6份和苯甲酸10份。
实施例12
一种治疗深部真菌性皮肤病的外用杀菌剂由以下重量份数的原料制得:
甘氨酸8份,硼酸9份,单宁酸6份,水杨酸8份和苯甲酸8份。
本发明实施例9~12制备的治疗深部真菌性皮肤病的外用杀菌剂为Ⅲ型(粉末状),治疗过程中取15~20份实施例9~12制备的治疗深部真菌性皮肤病的外用杀菌剂,置于1200~1500mL 50℃热水中制成药液,将患处(例如:深部真菌引起的脚气、脚臭、下肢慢性溃疡及鹅掌疯等病症)浸没于药液浸泡,两周为一疗程。当遇到病情较严重的脚癣及鹅掌疯,需要与Ⅰ型治疗深部真菌性皮肤病的外用杀菌剂配合使用(先用Ⅲ型治疗深部真菌性皮肤病的外用杀菌剂浸泡,再敷Ⅰ型治疗深部真菌性皮肤病的外用杀菌剂),愈后不复发。
本发明以上的Ⅰ型治疗深部真菌性皮肤病的外用杀菌剂(膏状)、Ⅱ型治疗深部真菌性皮肤病的外用杀菌剂(液体)及Ⅲ型治疗深部真菌性皮肤病的外用杀菌剂(粉末状),各有不同的功能,Ⅰ型促进患处新陈代谢及修复功能突出,Ⅱ型杀菌效好,Ⅲ型渗透力强,可以根据不同的病症及严重程度搭配使用,对皮肤无任何刺激作用,用药期间无需忌口,适用于各类人群。
虽然,上文中已经用一般性说明及具体实施例对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (9)
1.一种治疗深部真菌性皮肤病的外用杀菌剂,其特征在于:所述外用杀菌剂按照质量份数包括:甘氨酸3~12份、硼酸1~9份、单宁酸3~8份、水杨酸5~12份和苯甲酸6~12份。
2.根据权利要求1所述的治疗深部真菌性皮肤病的外用杀菌剂,其特征在于:所述外用杀菌剂按照质量份数还包括丙三醇3~80份。
3.根据权利要求2所述的治疗深部真菌性皮肤病的外用杀菌剂,其特征在于:所述丙三醇的浓度为50%或100%的丙三醇溶液。
4.根据权利要求1-3任一项所述的治疗深部真菌性皮肤病的外用杀菌剂,其特征在于:所述外用杀菌剂按照质量份数包括:甘氨酸3~8份、硼酸3~7份、单宁酸3~7份、水杨酸8~12份、苯甲酸6~12份、100%丙三醇溶液3~8份和纯化水18~35份。
5.根据权利要求1-3任一项所述的治疗深部真菌性皮肤病的外用杀菌剂,其特征在于:所述外用杀菌剂按照质量份数包括:甘氨酸5~10份、硼酸1~5份、单宁酸3~8份、水杨酸6~10份、苯甲酸5~8份、50%丙三醇溶液60~80份和纯化水20~30份。
6.根据权利要求1所述的治疗深部真菌性皮肤病的外用杀菌剂,其特征在于:所述外用杀菌剂按照质量份数包括:甘氨酸8~12份,硼酸4~9份,单宁酸5~8份,水杨酸5~8份和苯甲酸6~10份。
7.根据权利要求4所述的治疗深部真菌性皮肤病的外用杀菌剂,其特征在于:用于杀菌、去腐生肌、促进新陈代谢及治疗灰指甲。
8.根据权利要求5所述的治疗深部真菌性皮肤病的外用杀菌剂,其特征在于:用于治疗深部真菌引起的头癣、手癣、足癣、股癣及湿疹、寻麻疹。
9.根据权利要求6所述的治疗深部真菌性皮肤病的外用杀菌剂,其特征在于:用于治疗深部真菌引起的脚气、脚臭、下肢慢性溃疡及鹅掌疯。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710327689.2A CN107050049A (zh) | 2017-05-10 | 2017-05-10 | 一种治疗深部真菌性皮肤病的外用杀菌剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710327689.2A CN107050049A (zh) | 2017-05-10 | 2017-05-10 | 一种治疗深部真菌性皮肤病的外用杀菌剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107050049A true CN107050049A (zh) | 2017-08-18 |
Family
ID=59596115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710327689.2A Pending CN107050049A (zh) | 2017-05-10 | 2017-05-10 | 一种治疗深部真菌性皮肤病的外用杀菌剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107050049A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108904528A (zh) * | 2018-07-26 | 2018-11-30 | 哈尔滨快好药业有限公司 | 一种具有皮肤杀菌作用的化学组合物颗粒及其制备方法和应用 |
-
2017
- 2017-05-10 CN CN201710327689.2A patent/CN107050049A/zh active Pending
Non-Patent Citations (3)
Title |
---|
王会芸: "四酸粉治疗手足癣500例观察报告", 《贵州医药》 * |
程天恩等: "《防菌防霉剂手册》", 31 March 1993, 上海科学技术文献出版社 * |
陈安兰等: "四酸涂膜剂的研制及应用", 《金陵医院学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108904528A (zh) * | 2018-07-26 | 2018-11-30 | 哈尔滨快好药业有限公司 | 一种具有皮肤杀菌作用的化学组合物颗粒及其制备方法和应用 |
CN108904528B (zh) * | 2018-07-26 | 2020-12-29 | 黑龙江乐泰药业有限公司 | 一种具有皮肤杀菌作用的化学组合物颗粒及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bedi et al. | Herbal therapy in dermatology | |
CN105142728B (zh) | 用于治疗表面创伤的组合物和方法 | |
Hartman et al. | Two US practitioners' experience of using essential oils for wound care | |
CN102283899B (zh) | 一种中药外用制剂及其用途 | |
CN102755573A (zh) | 一种治疗灰指甲的外用中药 | |
CN101259149A (zh) | 治疗脚气的酊剂 | |
US20120219640A1 (en) | Anti-infective solution for athlete's foot | |
CN107050049A (zh) | 一种治疗深部真菌性皮肤病的外用杀菌剂 | |
CN105687021A (zh) | 防治脚癣的爽足粉 | |
CN102988277A (zh) | 一种治疗皮肤疣、甲真菌病和胼胝等皮肤病的油膏 | |
CN101810720A (zh) | 一种全面杀菌抑菌消炎的皮肤病外用药粉及其在脚气皮肤病上的使用方法 | |
CN104147584A (zh) | 一种治疗脚气的药物及其制作方法 | |
CN101411837A (zh) | 一种治疗脚癣的中药外用酊剂 | |
CN105996146A (zh) | 一种治疗脚气的祛汗除臭袜及其生产方法 | |
CN101912450A (zh) | 一种治疗脚气皮炎的中西药组合物及其制备方法 | |
CN101721547B (zh) | 一种治疗灰指甲的药物 | |
CN103372077A (zh) | 一种治疗脚湿气的药物 | |
CN102726464A (zh) | 一种中药消毒液配方及用此消毒液浸泡的鞋垫 | |
RU2736486C1 (ru) | Способ лечения чесотки | |
US11318182B1 (en) | Plant extract for skin infections | |
CN104000919A (zh) | 一种中药组合物 | |
Falkland | Over the counter: Topical treatment of tinea infections | |
CN117180343A (zh) | 一种治疗皮肤癣病的中药组合物及其应用 | |
CN101352521A (zh) | 灰指(趾)甲药及其制备方法 | |
CN1062761C (zh) | 多功能消痛液及其制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |